<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402623</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 05.142.5</org_study_id>
    <nct_id>NCT00402623</nct_id>
  </id_info>
  <brief_title>The Effect of Quercetin in Sarcoidosis</brief_title>
  <official_title>The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The exact cause of the chronic lung disease sarcoidosis is still unknown. Consequently, a
      complete efficacious treatment is still not available. Earlier studies indicate an important
      key role for oxidative stress, i.e. an imbalance between the production of and the protection
      against ROS, in the etiology of sarcoidosis. Antioxidants, needed for protection against ROS,
      are indeed lower in sarcoidosis. Therefore, antioxidant therapy to strengthen the reduced
      antioxidant defense might be efficacious in sarcoidosis treatment. Since ROS are also capable
      of initiating and mediating inflammation, antioxidant therapy might also mitigate the
      elevated inflammation that occurs in sarcoidosis. The flavonoid quercetin possesses both
      anti-oxidative and anti-inflammatory capacities and might therefore serve as a good candidate
      for antioxidant therapy in sarcoidosis.

      Therefore, the aim of the present study is to determine the effect of quercetin
      supplementation in sarcoidosis patients on markers of both oxidative stress and inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>antioxidant status after 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammatory status after 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma quercetin concentration after 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma malondialdehyde (MDA) levels after 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>quercetin (food supplement)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>quercetin</intervention_name>
    <description>1000 mg quercetin within 24 hours</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of sarcoidosis with emphasize on pulmonary sarcoidosis

          -  no smoking

          -  no treatment

        Exclusion Criteria:

          -  clinical diagnosis (and treatment) of other diseases

          -  symptoms of sarcoidosis in other organs besides the lung

          -  use of food supplements or vitamins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aalt Bast, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Agnes W Boots, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guido R Haenen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <zip>6200 MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2006</study_first_submitted>
  <study_first_submitted_qc>November 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <name_title>Dr. A.W. Boots</name_title>
    <organization>Maastricht University</organization>
  </responsible_party>
  <keyword>sarcoidosis</keyword>
  <keyword>quercetin</keyword>
  <keyword>supplementation</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

